No. 049 · Combos · Peptide Blend
Wolverine Stack
Also known as: Wolverine blendBPC-157 + TB-500
- Not approved as a combo
- WADA ✗ S0, S2
Combos are blends of separate compounds, so there is no single sequence. This ring motif is decorative — open a component for its fingerprint.
Quick answers
- What is Wolverine Stack?
- A popular recovery-focused blend typically combining BPC-157 and TB-500 for synergistic tissue repair. BPC-157 and TB-500 sold together (typically co-administered or pre-mixed).
- What is in Wolverine Stack?
- Wolverine Stack typically combines BPC-157 and TB-500. Commercial products vary.
- How strong is the evidence for Wolverine Stack?
- It is not ranked. A PubMed search found no published studies of this combination; only reviews mention it. BPC-157 and TB-500 (a thymosin β4 fragment) are each supported mainly by animal studies.
- Is Wolverine Stack FDA-approved?
- No. Wolverine Stack is not an approved product; no regulator has reviewed the combination.
- Is Wolverine Stack banned in sport?
- Yes. Wolverine Stack is prohibited in sport by the World Anti-Doping Agency under S0, S2.
- How does Wolverine Stack work?
- The Wolverine Stack combines two complementary healing pathways: BPC-157 activates FAK-paxillin and VEGFR2-mediated angiogenesis while modulating the nitric oxide system, and TB-500 promotes actin-dependent cell migration and integrin-linked kinase activation. Together they address both vascular supply and cellular migration components of tissue repair.
- What is known about the safety of Wolverine Stack?
- Safety evidence for each component comes mainly from animal studies; human safety data are minimal. No combination-specific safety data published.
Last reviewed · editorial policy · markdown
Evidence
- D In vitro
- C Animal
- B Human pilot
- A RCT
- S Approved
Not ranked: combinations have no published studies of their own. See the components below.
A PubMed search found no published studies of this combination; only reviews mention it. BPC-157 and TB-500 (a thymosin β4 fragment) are each supported mainly by animal studies.
Tiers rate the strength of published evidence — not effectiveness, safety, or a recommendation.
At a glance
- Routes studied
- Subcutaneous, Intramuscular Routes used in published research
- FDA
- Not approved as a combination
- WADA
- Prohibited · S0, S2
Overview
A popular recovery-focused blend typically combining BPC-157 and TB-500 for synergistic tissue repair. Named for its reputation of accelerating healing from injuries.
Research status No published studies of the combination; BPC-157 and TB-500 are each supported mainly by animal studies; use of the combination is based on anecdotal reports
Mechanism
The Wolverine Stack combines two complementary healing pathways: BPC-157 activates FAK-paxillin and VEGFR2-mediated angiogenesis while modulating the nitric oxide system, and TB-500 promotes actin-dependent cell migration and integrin-linked kinase activation. Together they address both vascular supply and cellular migration components of tissue repair.
Effects reported in research
These outcomes are attributed to the individual components. The combination itself has not been studied.
- Synergistic soft tissue repair
- Accelerated tendon and ligament healing
- Reduced inflammation and scar tissue
- Improved joint and connective tissue health
Safety & unknowns
Safety evidence for each component comes mainly from animal studies; human safety data are minimal. No combination-specific safety data published. Theoretical concerns include TB-500's pro-angiogenic activity. Neither component is FDA-approved, and both are prohibited in sport (WADA).
Unknowns. The combination itself has not been studied; interactions between its components are unknown.
Informational only — not medical advice. peptidemeta publishes no dosing, protocols, or sourcing. Talk to a qualified clinician about any treatment decision.
Studies [2]
- Review 2018
Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing
Review of the BPC-157 component by its originating group, summarizing animal studies of endothelial protection, thrombosis, and gastrointestinal healing.
- Preclinical 2004
Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair
Mouse and cell study on full-length thymosin β4 (the parent protein of the TB-500 fragment) showing it promoted cardiomyocyte migration and survival via integrin-linked kinase and improved cardiac function after coronary ligation.
Components
Status sources
Sources behind the tier, regulatory status, sequence and dates on this page.
- Review of BPC-157, thymosin β4 and TB-500 evidence in orthopaedics (JAAOS 2026) pubmed.ncbi.nlm.nih.gov
- WADA 2026 Prohibited List — BPC-157 named under S0; TB-500 under S2 wada-ama.org
Cite this entry
peptidemeta. (2026). Wolverine Stack. In peptidemeta: The peptide library, ranked by evidence. Retrieved November 8, 2026, from https://peptidemeta.com/p/wolverine-stack/
@misc{peptidemeta-wolverine-stack,
title = {Wolverine Stack},
author = {{peptidemeta}},
year = {2026},
howpublished = {\url{https://peptidemeta.com/p/wolverine-stack/}},
note = {Accessed 2026-11-08}
} Accessed date reflects when you opened this page. Cite primary studies for scientific claims.